ABX-EGF — Competitive Intelligence Brief

ABX-EGF (ABX-EGF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: growth factor. Area: Wound healing.

phase 2 growth factor EGF receptor Wound healing Small molecule

Target snapshot

ABX-EGF (ABX-EGF) — Amgen. ABX-EGF is a recombinant human heparin-binding EGF-like growth factor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABX-EGF TARGET	ABX-EGF	Amgen	phase 2	growth factor	EGF receptor
anti-VEGF agent	anti-VEGF agent	Medical University of Vienna	marketed	Anti-angiogenic agent (VEGF inhibitor)	VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors
DMX-200	DMX-200	Dimerix Bioscience Pty Ltd	phase 3	Dual VEGF/Ang2 inhibitor	VEGF receptor and Ang2 receptor (Tie2)
AG-013736	AG-013736	University of Wisconsin, Madison	phase 3	Multi-targeted tyrosine kinase inhibitor	VEGFR (VEGF receptor), PDGFR, and other receptor tyrosine kinases
Anti-VEGF Therapy	Anti-VEGF Therapy	Hoffmann-La Roche	phase 3	VEGF inhibitor	VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors
verteporfin, bevacizumab, triamcinolone acetonide	verteporfin, bevacizumab, triamcinolone acetonide	Shahid Beheshti University of Medical Sciences	phase 3	photosensitizer, monoclonal antibody, corticosteroid	VEGF-A, VEGF receptor
HR17031 injection	HR17031 injection	Jiangsu HengRui Medicine Co., Ltd.	phase 3	VEGF inhibitor	VEGF receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (growth factor class)

1. Amgen · 1 drug in this class
2. Austin Institute for Clinical Research · 1 drug in this class
3. Olympus Biotech Corporation · 1 drug in this class